Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Prednisolone | Case Report

A case of unexpected diagnosis of fibronectin glomerulopathy with histological features of membranoproliferative glomerulonephritis

Authors: Misa Hata, Takayasu Mori, Yurika Hirose, Yuriko Nishida, Shintaro Mandai, Fumiaki Ando, Koichiro Susa, Soichiro Iimori, Shotaro Naito, Eisei Sohara, Tatemitsu Rai, Towako Taguchi, Shohei Tomii, Kenichi Ohashi, Shinichi Uchida

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Fibronectin (FN) glomerulopathy (FNG), a rare autosomal hereditary renal disease, is characterized by proteinuria resulting from the massive accumulation of FN in the glomeruli. It typically affects individuals aged 10–50 years. In this report, we describe the case of a 57-year-old man who was diagnosed with FNG through genetic analysis and histological examination that revealed membranoproliferative glomerulonephritis. Despite treatment with prednisolone, the therapeutic response was unsatisfactory. Prednisolone was subsequently tapered and discontinued because the patient had pulmonary thromboembolism. Subsequent comprehensive genetic testing, which was initially not conducted because the patient’s parents did not have a history of kidney disease, identified a known disease-causing variant in the FN1 gene, indicating a de novo variant. FNG was further confirmed by positive staining of glomeruli with FN using an IST-4 antibody. Although corticosteroid therapy is commonly employed as the initial treatment for MPGN, its appropriateness depends on the underlying etiology. Thus, clinicians must be aware of potential rare genetic causes underlying MPGN.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gemperle O, Neuweiler J, Reutter FW, Hildebrandt F, Krapf R. Familial glomerulopathy with giant fibrillar (fibronectin-positive) deposits: 15-year follow up in a large kindred. Am J Kidney Dis. 1996;28(5):668–75.CrossRefPubMed Gemperle O, Neuweiler J, Reutter FW, Hildebrandt F, Krapf R. Familial glomerulopathy with giant fibrillar (fibronectin-positive) deposits: 15-year follow up in a large kindred. Am J Kidney Dis. 1996;28(5):668–75.CrossRefPubMed
2.
go back to reference Masabumi Y, Naoto M, Takahiro O, Keisuke S, Wataru K, Kazuhiro N, et al. Clinicopathological analysis of glomerulopathy with fibronectin deposits (GFND): a case of sporadic, elderly-onset GFND with codeposition of IgA, C1q, and fibrinogen. Intern Med. 2013;52(15):1715–20.CrossRef Masabumi Y, Naoto M, Takahiro O, Keisuke S, Wataru K, Kazuhiro N, et al. Clinicopathological analysis of glomerulopathy with fibronectin deposits (GFND): a case of sporadic, elderly-onset GFND with codeposition of IgA, C1q, and fibrinogen. Intern Med. 2013;52(15):1715–20.CrossRef
3.
go back to reference Wang T, Bw H. Fibronectin glomerulopathy: a case report and literature review. Nefrogia (Engl Ed). 2021;41(1):74–6.CrossRef Wang T, Bw H. Fibronectin glomerulopathy: a case report and literature review. Nefrogia (Engl Ed). 2021;41(1):74–6.CrossRef
4.
go back to reference Mori T, Kazuyoshi H, Motoko C, Shintaro M, Hirofumi N, Eisei S, et al. Comprehensive genetic testing approach for major inherited kidney diseases, using next-generation sequencing with a custom panel. Clin Exp Nephrol. 2017;21(1):63–75.CrossRefPubMed Mori T, Kazuyoshi H, Motoko C, Shintaro M, Hirofumi N, Eisei S, et al. Comprehensive genetic testing approach for major inherited kidney diseases, using next-generation sequencing with a custom panel. Clin Exp Nephrol. 2017;21(1):63–75.CrossRefPubMed
5.
go back to reference Ohtsubo H, Taro O, Kandai N, Yutaka T, Akemi S, Katsuhiro A, et al. Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits. Pediatr Nephrol. 2016;31(9):1459–67.CrossRefPubMed Ohtsubo H, Taro O, Kandai N, Yutaka T, Akemi S, Katsuhiro A, et al. Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits. Pediatr Nephrol. 2016;31(9):1459–67.CrossRefPubMed
6.
go back to reference Castelletti F, Donadelli R, Banterla F, Hildebrandt F, Zipfel PF, Bresin E, et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci USA. 2008;105(7):2538–43.CrossRefPubMedPubMedCentral Castelletti F, Donadelli R, Banterla F, Hildebrandt F, Zipfel PF, Bresin E, et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci USA. 2008;105(7):2538–43.CrossRefPubMedPubMedCentral
7.
go back to reference Wu C. Integrin mediated fibronectin matrix assembly. Trends Glycosci Glycotechnol. 1996;43(8):315–25.CrossRef Wu C. Integrin mediated fibronectin matrix assembly. Trends Glycosci Glycotechnol. 1996;43(8):315–25.CrossRef
8.
go back to reference Oh GJ, Waldo A, Paez-Cruz F, Gipson PE, Pesenson A, Selewski DT, et al. Steroid-associated side effects in patients with primary proteinuric kidney disease. Kidney Int Rep. 2019;4(11):1608–16.CrossRefPubMedPubMedCentral Oh GJ, Waldo A, Paez-Cruz F, Gipson PE, Pesenson A, Selewski DT, et al. Steroid-associated side effects in patients with primary proteinuric kidney disease. Kidney Int Rep. 2019;4(11):1608–16.CrossRefPubMedPubMedCentral
9.
go back to reference Noris M, Remuzzi G. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol. 2008;151(2):199–209.CrossRefPubMedPubMedCentral Noris M, Remuzzi G. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol. 2008;151(2):199–209.CrossRefPubMedPubMedCentral
10.
go back to reference Goldman BI, Panner BJ, Welle SL, Gross MD, Gray DA. Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND). CEN Case Rep. 2021;10(4):510–4.CrossRefPubMedPubMedCentral Goldman BI, Panner BJ, Welle SL, Gross MD, Gray DA. Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND). CEN Case Rep. 2021;10(4):510–4.CrossRefPubMedPubMedCentral
11.
go back to reference Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, et al. Effects of short-term glucocorticoids on hemo-static factors in healthy volunteers. Thromb Res. 2006;118(2):247–52.CrossRefPubMed Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, et al. Effects of short-term glucocorticoids on hemo-static factors in healthy volunteers. Thromb Res. 2006;118(2):247–52.CrossRefPubMed
Metadata
Title
A case of unexpected diagnosis of fibronectin glomerulopathy with histological features of membranoproliferative glomerulonephritis
Authors
Misa Hata
Takayasu Mori
Yurika Hirose
Yuriko Nishida
Shintaro Mandai
Fumiaki Ando
Koichiro Susa
Soichiro Iimori
Shotaro Naito
Eisei Sohara
Tatemitsu Rai
Towako Taguchi
Shohei Tomii
Kenichi Ohashi
Shinichi Uchida
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03456-7

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.